



Contra Costa Health Plan
P&T Formulary Update
June 4, 2020

Volume 14

Changes effective: 7/10/2020

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On June 4, 2020 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
• Intra-articular hyaluronic acids • CGRP antagonists • ICS/LAMA/LABA agents • Non-opioid (neuropathic) pain management agents • Nasal steroids • Potassium binding agents	• Gout Agents • Narcolepsy Agents • Contraceptives, foams, and devices • ADHD medications • Anti-obesity medications • Opioid dependence agents
Drug Monographs	
• Reyvow • Oxbryta • Adakveo • Palforzia • Sucraid • Ridaura	
Prior Authorization Criteria Updates	
<u>New criteria was created for the following agents:</u> • Rectiv (nitroglycerin) • Acute migraine medications (Nurtec ODT, Reyvow, Ubrelvy) <u>Updates were made to the criteria for the following agents:</u> • Entresto (sacubitril/valsartan) • Adalimumab (Humira) • Infliximab (Remicade) • Maraviroc (Selzentry) • Tofacitinib (Xeljanz) • Ustekinumab (Stelara) • Valbenazine (Ingrezza)	

Criteria reviewed and unchanged:

- Gout agents
- Narcolepsy agents

The following drugs were added to the CCHP formulary:

- Ozempic (semaglutide), Rybelsus (semaglutide)
- Farxiga (dapagliflozin)
- Lidocaine 5% ointment
- Lidocaine/prilocaine 2.5%-2.5% cream

Guest Speaker(s)

- None

CCHP P&T Committee approved the following modifications to the formulary:

Medication Name & Dosage Strength	Approved Formulary Changes
Ozempic (semaglutide)	Added to formulary, Tier 2 QL
Rybelsus (semaglutide)	Added to formulary, Tier 2 QL
Farxiga (dapagliflozin)	Added to formulary, Tier 2 QL
Lidocaine 5% ointment	Added to formulary, Tier 1
Lidocaine/prilocaine 2.5-2.5% cream	Added to formulary, Tier 2 QL

New Product Reviews (including new indications)

- | | |
|--|---|
| <ul style="list-style-type: none"> • Ruxience (rituximab-pvvr) • Tazverik (Tazemetostat) • Reyvow (Lasmiditan) • Palforzia (Peanut allergen powder) • Fetroja (Cefiderocol) • Procysbi (Cysteamine bitartrate) • Trazimera (Trastuzumab-qyyp) • Lipiodol (Ethiodized oil) • Vyepti (Eptinezumab-jjmr) • Nurtec ODT (Rimegepant ODT) • Nexletol (Bempedoic acid) • Zerviate (Cetirizine ophthalmic) | <ul style="list-style-type: none"> • Sarclisa (Isatuximab-irfc) • Trijardy XR (Empagliflozin/linagliptin/metformin ER) • Scenesse (Afamelanotide SQ) • Arazlo (Tazarotene) topical lotion • Xcopri (Cenobamate) tablet • Ajovy (Fremanezumab-vfrm) • Isturisa (Osilodrostat) tablets • Ontruzant (Trastuzumab-dttb) • Koselugo (Selumetinib) capsules • Tukysa (Tucatinib) tablets • Pemazyre (Pemigratinib) tablets |
|--|---|